Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $19.59
by Kim Johansen · The Markets DailyShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have received a consensus recommendation of “Hold” from the twenty brokerages that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $19.5909.
Several research analysts have recently weighed in on the stock. reissued a “buy” rating on shares of Intellia Therapeutics in a report on Tuesday, March 3rd. Robert W. Baird set a $7.00 target price on shares of Intellia Therapeutics in a report on Tuesday, January 27th. Wall Street Zen upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. HC Wainwright increased their price target on Intellia Therapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Finally, Leerink Partners raised their price target on Intellia Therapeutics from $27.00 to $29.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 3rd.
Read Our Latest Analysis on NTLA
Insider Buying and Selling at Intellia Therapeutics
In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at $907,488.93. The trade was a 7.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is owned by company insiders.
Institutional Trading of Intellia Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Contrarius Group Holdings Ltd increased its holdings in Intellia Therapeutics by 279.4% during the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after buying an additional 4,337,428 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Intellia Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after acquiring an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp grew its position in shares of Intellia Therapeutics by 29.1% during the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after acquiring an additional 1,447,967 shares during the period. Finally, Jupiter Asset Management Ltd. purchased a new stake in shares of Intellia Therapeutics in the 3rd quarter worth $23,519,000. 88.77% of the stock is currently owned by institutional investors.
Intellia Therapeutics Stock Performance
NASDAQ NTLA opened at $13.13 on Tuesday. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.25. The stock has a 50-day moving average of $13.07 and a 200 day moving average of $13.35. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -3.43 and a beta of 1.99.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The business’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.27) EPS. On average, equities analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.